微信关注
China
Total item
Cart Subtotal
￥ 0.00 Angiogenesis
Angiogenesis is the formation and remodelling of new blood vessels and capillaries from growth of pre-existing blood vessels. It normally occurs during wound healing and embryonic development, but is also required for tumour growth and metastasis in cancer.
-
Defactinib
Catalog No. A21958 FAK inhibitorDefactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities. 了解更多 -
Defactinib hydrochloride
Catalog No. A22003 FAK inhibitorDefactinib hydrochloride (VS-6063 hydrochloride; PF 04554878 hydrochloride) is a novel FAK inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner. 了解更多 -
PF-03814735
Catalog No. A11171 Aurora A/B Kinase 抑制剂PF-03814735是一种新颖，有效且可逆的Aurora A/B抑制剂，IC50为0.8 nM/5 nM，对Flt3，FAK，TrkA的效力较低，对Met和FGFR1的活性最低。 了解更多 -
PF-00562271
Catalog No. A12580 FAK 抑制剂PF-00562271是PF-562271的苯磺酸盐，是一种有效的，ATP竞争性，可逆的FAK和Pyk2抑制剂，IC50分别为1.5 nM和14 nM。 了解更多 -
PF-4618433
Catalog No. A13461 -
R788 (Fostamatinib)
Catalog No. A11926 Syk 抑制剂R788 (Fostamatinib)是重要的脾酪氨酸激酶（Syk）抑制剂，显示出对激酶介导的IgG Fcγ受体信号转导的功效。 了解更多 -
BAY 61-3606
Catalog No. A11320 Syk 抑制剂BAY 61-3606是一种细胞可渗透的咪唑并嘧啶化合物，可作为Syk酪氨酸激酶活性的有效，ATP竞争性，可逆和高度选择性抑制剂，而对Btk，Fyn，Itk，Lyn和Src无抑制作用。 了解更多 -
P505-15 (PRT062607, BIIB057)
Catalog No. A11952 Syk 抑制剂P505-15 (PRT062607,BIIB057)是一种新型的，高度选择性的，Syk抑制剂（SYK IC（50）= 1 nM），具有比SYK活性至少高80倍的抗SYK活性。 了解更多 -
PRT 062070 (Cerdulatinib)
Catalog No. A14147 Dual Syk and JAK 抑制剂PRT 062070 (Cerdulatinib)是一种新型的口服双脾酪氨酸激酶（Syk）和janus激酶（JAK）抑制剂。Cerdulatinib优先抑制各种细胞类型中JAK1和JAK3依赖性细胞因子介导的信号传导和功能性反应。 了解更多 -
BAY 61-3606 dihydrochloride
Catalog No. A15017 -
R112
Catalog No. A14161 -
Lanraplenib
Catalog No. A12959 SYK inhibitorLanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. 了解更多 -
Fostamatinib disodium hexahydrate
Catalog No. A21873 Syk inhibitorFostamatinib disodium hexahydrate (R788 disodium hexahydrate), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM. 了解更多 -
TAK-659 hydrochloride
Catalog No. A21885 Syk inhibitorTAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM. 了解更多 -
R935788 (Fostamatinib disodium, R788)
Catalog No. A10771 Syk 抑制剂R935788 (Fostamatinib disodium,R788)是一种有效的口服Syk抑制剂，可通过阻断抗原依赖性B细胞受体信号传导来抑制CLL的Eμ-TCL1转基因小鼠模型中的肿瘤生长。 了解更多 -
Piceatannol
Catalog No. A12162 -
GS-9973 (Entospletinib)
Catalog No. A13884 -
PRT062607 HCL
Catalog No. A12731 Syk 抑制剂PRT2607，也称为PRT062607，P505-15和BIIB057，是一种新型，高度选择性且口服可生物利用的小分子SYK抑制剂（SYK IC（50）= 1 nM），具有至少80倍的抗SYK活性 大于对其他激酶的亲和力。 了解更多 -
Gusacitinib
Catalog No. A19883 SYK/JAK inhibitorGusacitinib (ASN-002) is a potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. 了解更多 -
Dasatinib (BMS-354825)
Catalog No. A10290 Abl-Src 抑制剂Dasatinib (BMS-354825)是一种口服多BCR/ABL和Src家族酪氨酸激酶抑制剂。Dasatinib (BMS-354825)的主要靶标是BCR/ABL，Src，c-Kit，ephrin受体和其他几种酪氨酸激酶，但不是erbB激酶，例如EGFR或Her2。 了解更多 -
Saracatinib (AZD0530)
Catalog No. A10108 Src/Abl 抑制剂Saracatinib (AZD0530)是一种高选择性，双特异性Src/Abl激酶抑制剂，对c-Src和Abl激酶的IC50分别为2.7和30 nM。 了解更多 -
Bafetinib (INNO-406)
Catalog No. A10119 Bcr-Abl 抑制剂Bafetinib (INNO-406)是一种双重Bcr-Abl/Lyn酪氨酸激酶抑制剂。 了解更多 -
Nilotinib (AMN-107)
Catalog No. A10644 Bcr-Abl 抑制剂Nilotinib (AMN-107)是一种Bcr-Abl抑制剂，IC50小于30 nM。 了解更多 -
NVP-BHG712
Catalog No. A10661 EphB4 抑制剂NVP-BHG712是EphB4激酶的选择性抑制剂，在体外对EphB4的选择性超过40多种其他激酶（包括FGFR3）。 了解更多 -
DCC-2036 (Rebastinib)
Catalog No. A11200 Bcr-Abl 抑制剂DCC-2036 (Rebastinib)是一种Bcr-Abl抑制剂，作用于Abl1(WT)和Abl1(T315I)，IC50分别为0.8 nM和4 nM，也抑制SRC， LYN， FGR， HCK， KDR， FLT3，和Tie-2，对c-Kit具有低的抑制活性。 了解更多 -
GZD824 Dimesylate
Catalog No. A15849 Bcr-Abl 抑制剂GZD824 Dimesylate是Bcr-Abl（WT）和Bcr-Abl（T315I）的新型生物可用Bcr-Abl抑制剂，IC50分别为0.34 nM和0.68 nM。 了解更多 -
Lyn-IN-1
Catalog No. A16265 -
SNIPER(ABL)-062
Catalog No. A18567 ABL inhibitorSNIPER(ABL)-062, in which an ABL inhibitor is linked to a ligand of cIAP1 via a linker containing a variable polyethylene glycol (PEG) unit, shows a potent activity to degrade the BCR-ABL protein. 了解更多 -
CHMFL-ABL-121
Catalog No. A19079 ABL2 inhibitorCHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively. 了解更多 -
CHMFL-ABL-039
Catalog No. A13182 BCR-ABL inhibitorCHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor with the IC50s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia. 了解更多 -
BCR-ABL-IN-1
Catalog No. A12496 BCR-ABL inhibitorBCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia. 了解更多 -
CHMFL-ABL/KIT-155
Catalog No. A12421 ABL/c-KIT dual kinase inhibitorCHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor. 了解更多 -
1-Naphthyl PP1 hydrochloride
Catalog No. A21790 Src/c-Abl inhibitor1-Naphthyl PP1 hydrochloride is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). 了解更多 -
BCR-ABL-IN-2
Catalog No. A21043 inhibitor of BCR-ABL1 tyrosine kinaseBCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. 了解更多 -
WP1130 (Degrasyn)
Catalog No. A10988 DUB/Bcr/ABL 抑制剂WP1130 (Degrasyn)是一种新型的选择性小分子去泛素酶抑制剂和Bcr/Abl破坏途径激活剂，可特异性和快速下调野生型和突变型Bcr/Abl蛋白，而不会影响慢性粒细胞性白血病（CML）中的bcr/abl基因表达细胞。 了解更多 -
GNF 2
Catalog No. A11439 -
PD173955
Catalog No. A13120 Bcr-Abl 抑制剂PD-173955是src酪氨酸激酶抑制剂。PD173955抑制Bcr-Abl依赖的细胞生长。PD173955显示G（1）中的细胞周期停滞。PD173955在Bcr-Abl的激酶抑制测定中的IC（50）为1-2 nM，在细胞生长测定中，其抑制Bcr-Abl依赖性底物酪氨酸磷酸化。 PD173955抑制试剂盒配体依赖性c-kit自磷酸化（IC（50）=约25 nM）和试剂盒配体依赖性M07e细胞增殖（IC（50）= 40 nM），但对白介素3依赖性（IC （50）= 250 nM）或粒细胞巨噬细胞集落刺激因子（IC（50）= 1 microM）依赖性细胞生长。 了解更多 -
NRC-AN-019
Catalog No. A13562 Bcr-Abl 抑制剂NRC-AN-019是Bcr-Abl蛋白-酪氨酸激酶的口服酪氨酸激酶抑制剂（TKI）。NRC-AN-019在抑制MDAMB231和HTB20/BT474细胞的血管生成潜力和增殖方面更有效。 了解更多
FILTER BY:
Filtering:
- 作用机制: Inhibitor (抑制剂) 删除该内容
购物选项
- 分类
- 靶点
-
- Abl (6)
- ALK (1)
- Aurora A (8)
- Aurora B (4)
- Aurora C (1)
- Axl (1)
- B-Raf (3)
- Bcr-Abl (1)
- C-Raf (Raf-1) (3)
- CDK (2)
- CDK2 (2)
- CDK4 (1)
- Chk2 (1)
- CSF1R (5)
- EGFR (23)
- EGFR Exon 19 Deletion (1)
- EGFR L858R (5)
- EGFR L861Q (2)
- EGFR T790M (9)
- EGFR wild type (2)
- EphB4 (2)
- ErbB2 (3)
- ErbB3 (1)
- ErbB4 (2)
- FAK (10)
- FGFR (2)
- FGFR1 (23)
- FGFR2 (11)
- FGFR3 (12)
- FGFR4 (9)
- FLT3 (28)
- HDAC (1)
- HER2 (2)
- IGF1R (1)
- JAK1 (1)
- JAK2 (9)
- JAK3 (3)
- Kit (14)
- Lck (1)
- Lyn (1)
- Mer (1)
- PDGFR (1)
- PDGFRα (10)
- PDGFRβ (18)
- PKCα (1)
- PKCβ (1)
- PYK2 (4)
- RET (6)
- Src (5)
- STAT1 (1)
- Syk (2)
- TrkA (2)
- VEGFR1 (FLT1) (12)
- VEGFR2 (FLK1) (25)
- VEGFR3 (FLT4) (11)
联系我们
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
Not your Region? View all Distributors
ADOOQ 产品质量保证
We promise all products to perform as described.